Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PathAI has launched over 20 new AI products across oncology, liver disease (MASH/MASLD), and IBD. Its platforms are used by more than half of the top global biopharma companies to accelerate drug development through improved pathology workflows. The company’s technology supports translational research projects (>100 completed) and has been used in at least two dozen clinical trials as of early 2024. Clinical results focus on improved accuracy/reproducibility of diagnosis rather than direct patient outcomes typical of therapeutics. The AISight® image management system has been launched and distributed to more than 50 labs globally. 90% of top biopharma companies leverage their technology, and 26 clinical trials are using PathAI algorithms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PathAI.